Session 2.2 | Renal Denervation for Uncontrolled Hypertension: Bridging Guidelines and Real World Practice

Chair: Deepak Bhatt

Panel: Tiffany Randolph; Jeremy Bock; Ajay Kirtane; Behnam Tehrani

With two FDA-approved systems and a Class IIb recommendation in the 2025 ACC/AHA guidelines, RDN is moving from proof-of-concept to clinical implementation. Dr Tiffany Randolph frames patient selection and the multidisciplinary team model. Dr Jeremy Bock and Dr Behnam Tehrani demonstrate radiofrequency and ultrasound-based denervation respectively, while Dr Ajay Kirtane addresses the critical question: how do we define procedural success? Practical, case-driven and directly applicable to building an RDN program.